These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 27017583)

  • 1. Rapid formulation assessment of filgrastim therapeutics by a thermal stress test.
    Alebouyeh M; Tahzibi A; Yaghoobzadeh S; Zahedy ET; Kiumarsi S; Soltanabad MH; Shahbazi S; Amini H
    Biologicals; 2016 May; 44(3):150-6. PubMed ID: 27017583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product.
    Halim LA; Márquez M; Maas-Bakker RF; Castañeda-Hernández G; Jiskoot W; Schellekens H
    Pharm Res; 2018 Oct; 35(11):226. PubMed ID: 30280277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Structural, Biological, and Functional Similarity of Biosimilar Granulocyte Colony Stimulating Factor to its Reference Product.
    Bor Tekdemir Z; Seckin AI; Kacar T; Yilmaz E; Bekiroglu S
    Pharm Res; 2020 Oct; 37(11):215. PubMed ID: 33026512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Adsorption of Original and Biosimilar Preparations of Filgrastim on Infusion Sets and the Inhibition of Adsorption by Polysorbate 80.
    Tange M; Matsumoto A; Yoshida M; Kojima H; Haraguchi T; Uchida T
    Chem Pharm Bull (Tokyo); 2017; 65(1):36-41. PubMed ID: 28049914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring Effects of Excipients, Formulation Parameters and Mutations on the High Order Structure of Filgrastim by NMR.
    Aubin Y; Hodgson DJ; Thach WB; Gingras G; Sauvé S
    Pharm Res; 2015 Oct; 32(10):3365-75. PubMed ID: 26043856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation of Neulasta (pegfilgrastim).
    Piedmonte DM; Treuheit MJ
    Adv Drug Deliv Rev; 2008 Jan; 60(1):50-8. PubMed ID: 17822802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical techniques and bioactivity assays to compare the structure and function of filgrastim (granulocyte-colony stimulating factor) therapeutics from different manufacturers.
    Levy MJ; Gucinski AC; Sommers CD; Ghasriani H; Wang B; Keire DA; Boyne MT
    Anal Bioanal Chem; 2014 Oct; 406(26):6559-67. PubMed ID: 24264620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous analysis of filgrastim and pegfilgrastim aggregates by size-exclusion chromatography.
    Tamaskany Zahedy E; Farzane Yegane D; Shahbazi M; Amini H
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Sep; 1152():122229. PubMed ID: 32563957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product.
    Sörgel F; Lerch H; Lauber T
    BioDrugs; 2010 Dec; 24(6):347-57. PubMed ID: 20873878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of liquid chromatographic and biological assay for potency assessment of filgrastim and related impurities.
    Skrlin A; Kosor Krnic E; Gosak D; Prester B; Mrsa V; Vuletic M; Runac D
    J Pharm Biomed Anal; 2010 Nov; 53(3):262-8. PubMed ID: 20478679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial.
    Lubenau H; Bias P; Maly AK; Siegler KE; Mehltretter K
    BioDrugs; 2009; 23(1):43-51. PubMed ID: 19344191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF).
    Lord BI; Woolford LB; Molineux G
    Clin Cancer Res; 2001 Jul; 7(7):2085-90. PubMed ID: 11448927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion.
    Guyader GL; Vieillard V; Paul M
    J Oncol Pharm Pract; 2021 Jun; 27(4):847-856. PubMed ID: 32660375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new site-specific monoPEGylated filgrastim derivative prepared by enzymatic conjugation: Production and physicochemical characterization.
    Scaramuzza S; Tonon G; Olianas A; Messana I; Schrepfer R; Orsini G; Caliceti P
    J Control Release; 2012 Dec; 164(3):355-63. PubMed ID: 22735238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Low-Level Product-Related Variants in Filgrastim Products Presently Available in Highly Regulated Markets.
    Hausberger A; Lamanna WC; Hartinger M; Seidl A; Toll H; Holzmann J
    BioDrugs; 2016 Jun; 30(3):233-42. PubMed ID: 27026103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDX and In Silico Docking Reveal that Excipients Stabilize G-CSF via a Combination of Preferential Exclusion and Specific Hotspot Interactions.
    Wood VE; Groves K; Cryar A; Quaglia M; Matejtschuk P; Dalby PA
    Mol Pharm; 2020 Dec; 17(12):4637-4651. PubMed ID: 33112626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim.
    Skrlin A; Radic I; Vuletic M; Schwinke D; Runac D; Kusalic T; Paskvan I; Krsic M; Bratos M; Marinc S
    Biologicals; 2010 Sep; 38(5):557-66. PubMed ID: 20637652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of gel-forming lyophilized formulation with recombinant human thrombin.
    Murányi A; Bartoš P; Tichý E; Lazová J; Pšenková J; Žabka M
    Drug Dev Ind Pharm; 2015; 41(9):1566-73. PubMed ID: 25347143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Excipients on the Structure and Dynamics of Filgrastim Monitored by Thermal Unfolding Studies by CD and NMR Spectroscopy.
    Ghasriani H; Frahm GE; Johnston MJW; Aubin Y
    ACS Omega; 2020 Dec; 5(49):31845-31857. PubMed ID: 33344838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ionic strength on the thermal unfolding process of granulocyte-colony stimulating factor.
    Yamazaki K; Iwura T; Ishikawa R; Ozaki Y
    J Biochem; 2006 Jan; 139(1):41-9. PubMed ID: 16428318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.